Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (941 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Lung damage that is caused by the adverse effects of pulmonary ventilator usage. The high frequency and tidal volumes produced by a mechanical ventilator can cause alveolar disruption and pulmonary edema.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Lung Injuries, Ventilator-Induced; Ventilator-Induced Lung Injuries; Ventilator Induced Lung Injury; Lung Injury, Ventilator-Induced; Lung Injury, Ventilator Induced.
Where it fits in the MeSH classification
- Broader topics
- Lung Injury
- Narrower topics
- Bronchopulmonary Dysplasia
- See also
- Ventilators, Mechanical
Related concepts
- Pulmonary Ventilator
- Pulmonary Edema
Research landscape
PubMed indexes 8,847 records tagged with the MeSH heading “Ventilator-Induced Lung Injury” (counts retrieved 2026-11-04). 3,092 of them (34.9%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 3,337 records.
Reviews account for 1,751 records (19.8%) and meta-analyses for 240. Randomized controlled trials number 468 (5.3%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1,239 |
| 2000-2009 | 1,179 |
| 2010-2019 | 3,337 |
| 2020 onward | 3,092 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 1,751 | 19.8% |
| Meta-analyses | 240 | 2.7% |
| Randomized controlled trials | 468 | 5.3% |
Method: PubMed query "Ventilator-Induced Lung Injury"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.
Reading the evidence in respiratory medicine
Research on airway and lung disease mixes lung-function tests, symptom diaries, imaging and hospital records, so what was measured and in whom matters as much as the result. Many conditions here, such as asthma and COPD, vary between people and over time, and exposure studies (smoking, pollution, workplace dust) show association rather than proof of cause. Nothing on this page is advice about treatment or inhalers; anyone with breathing difficulty should seek care from a qualified clinician. Check how the condition was defined, the severity of the people studied and whether outcomes were symptoms, lung function or hospital admissions.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Impaired myofibroblast proliferation is a central feature of pathologic post-natal alveolar simplification | 2024 | Research article Design not recorded in structured metadata | 15 | cc by PMID 39660606 · DOI · PMC11634066 |
| Fetal origin of bronchopulmonary dysplasia: contribution of intrauterine inflammation | 2024 | Review article Design not recorded in structured metadata | 15 | cc by PMID 39227783 · DOI · PMC11373297 |
| Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model | 2025 | Research article Design not recorded in structured metadata | 13 | cc by PMID 39394424 · DOI · PMC12119323 |
| Patient self-inflicted lung injury an important phenomenon | 2026 | Review article Design not recorded in structured metadata | 5 | cc by PMID 41359372 · DOI · PMC12746771 |
Impaired myofibroblast proliferation is a central feature of pathologic post-natal alveolar simplification [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Premature infants with bronchopulmonary dysplasia (BPD) have impaired alveolar gas exchange due to alveolar simplification and dysmorphic pulmonary vasculature.
- Closing excerpt
- Our results underscore the importance of impaired myofibroblast proliferation as a central feature of alveolar simplification and suggest that efforts to reverse this process could have therapeutic value in BPD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (243 words)
Premature infants with bronchopulmonary dysplasia (BPD) have impaired alveolar gas exchange due to alveolar simplification and dysmorphic pulmonary vasculature. Advances in clinical care have improved survival for infants with BPD, but the overall incidence of BPD remains unchanged because we lack specific therapies to prevent this disease. Recent work has suggested a role for increased transforming growth factor-beta (TGFβ) signaling and myofibroblast populations in BPD pathogenesis, but the functional significance of each remains unclear. Here, we utilize multiple murine models of alveolar simplification and comparative single-cell RNA sequencing to identify shared mechanisms that could contribute to BPD pathogenesis. Single-cell RNA sequencing reveals a profound loss of myofibroblasts in two models of BPD and identifies gene expression signatures of increased TGFβ signaling, cell cycle arrest, and impaired proliferation in myofibroblasts. Using pharmacologic and genetic approaches, we find no evidence that increased TGFβ signaling in the lung mesenchyme contributes to alveolar simplification. In contrast, this is likely a failed compensatory response, since none of our approaches to inhibit TGFβ signaling protect mice from alveolar simplification due to hyperoxia while several make simplification worse. In contrast, we find that impaired myofibroblast proliferation is a central feature in several murine models of BPD, and we show that inhibiting myofibroblast proliferation is sufficient to cause pathologic alveolar simplification. Our results underscore the importance of impaired myofibroblast proliferation as a central feature of alveolar simplification and suggest that efforts to reverse this process could have therapeutic value in BPD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39660606 · DOI · PMC11634066
Fetal origin of bronchopulmonary dysplasia: contribution of intrauterine inflammation [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in infants and the most frequent adverse outcome of premature birth, despite major efforts to minimize injury.
- Closing excerpt
- In addition, we discuss prenatal therapeutic strategies targeting intrauterine inflammation to prevent or treat BPD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (110 words)
Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in infants and the most frequent adverse outcome of premature birth, despite major efforts to minimize injury. It is thought to result from aberrant repair response triggered by either prenatal or recurrent postnatal injury to the lungs during development. Intrauterine inflammation is an important risk factor for prenatal lung injury, which is also increasingly linked to BPD. However, the specific mechanisms remain unclear. This review summarizes clinical and animal research linking intrauterine inflammation to BPD. We assess how intrauterine inflammation affects lung alveolarization and vascular development. In addition, we discuss prenatal therapeutic strategies targeting intrauterine inflammation to prevent or treat BPD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39227783 · DOI · PMC11373297
Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundBronchopulmonary dysplasia (BPD), the chronic lung disease associated with prematurity, is characterized by poor alveolar and vascular growth, interstitial fibrosis, and pulmonary hypertension (PH).
- Closing excerpt
- Currently, strategies for the prevention and treatment of BPD are lacking, especially in the context of lung fibrosis, so this research has major clinical applicability.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (380 words)
BackgroundBronchopulmonary dysplasia (BPD), the chronic lung disease associated with prematurity, is characterized by poor alveolar and vascular growth, interstitial fibrosis, and pulmonary hypertension (PH). Although multifactorial in origin, the pathophysiology of BPD is partly attributed to hyperoxia-induced postnatal injury, resulting in lung fibrosis. Recent work has shown that anti-fibrotic agents, including Nintedanib (NTD), can preserve lung function in adults with idiopathic pulmonary fibrosis. However, NTD is a non-specific tyrosine kinase receptor inhibitor that can potentially have adverse effects on the developing lung, and whether NTD treatment can prevent or worsen risk for BPD and PH is unknown.HypothesisWe hypothesize that NTD treatment will preserve lung growth and function and prevent PH in an experimental model of hyperoxia-induced BPD in rats.MethodsNewborn rats were exposed to either hyperoxia (90%) or room air (RA) conditions and received daily treatment of NTD or saline (control) by intraperitoneal (IP) injections (1 mg/kg) for 14 days, beginning on postnatal day 1. At day 14, lung mechanics were measured prior to harvesting lung and cardiac tissue. Lung mechanics, including total respiratory resistance and compliance, were measured using a flexiVent system. Lung tissue was evaluated for radial alveolar counts (RAC), mean linear intercept (MLI), pulmonary vessel density (PVD), and pulmonary vessel wall thickness (PVWT). Right ventricular hypertrophy (RVH) was quantified with cardiac weights using Fulton's index (ratio of right ventricle to the left ventricle plus septum).ResultsWhen compared with RA controls, hyperoxia exposure reduced RAC by 64% (p ConclusionsWe found that NTD treatment preserved lung alveolar and vascular growth, improved lung function, and reduced RVH in experimental BPD in infant rats without apparent adverse effects in control animals. We speculate that although potentially harmful at high doses, NTD may provide a novel therapeutic strategy for prevention of BPD and PH.ImpactAnti-fibrotic therapies may be a novel therapeutic strategy for the treatment or prevention of BPD. High-dose anti-fibrotics may have adverse effects on developing lungs, while low-dose anti-fibrotics may treat or prevent BPD. There is very little preclinical and clinical data on the use of anti-fibrotics in the developing lung. Dose timing and duration of anti-fibrotic therapies may be critical for the treatment of neonatal lung disease. Currently, strategies for the prevention and treatment of BPD are lacking, especially in the context of lung fibrosis, so this research has major clinical applicability.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39394424 · DOI · PMC12119323
Patient self-inflicted lung injury an important phenomenon [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Purpose of reviewMechanical ventilation is essential in acute hypoxemic respiratory failure (AHRF), yet excessive respiratory drive and inspiratory effort may aggravate injury, a phenomenon termed patient self-inflicted lung injury (P-SILI).
- Closing excerpt
- Preventive strategies should not abolish but shape effort, integrating ventilatory settings, sedation, and drive-modulating interventions across the continuum from the acute phase to weaning and rehabilitation.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (208 words)
Purpose of reviewMechanical ventilation is essential in acute hypoxemic respiratory failure (AHRF), yet excessive respiratory drive and inspiratory effort may aggravate injury, a phenomenon termed patient self-inflicted lung injury (P-SILI). This review summarizes mechanistic insights, preclinical and clinical evidence, and current strategies to prevent P-SILI while preserving diaphragmatic function.Recent findingsPreclinical experimental studies show that vigorous inspiratory efforts amplify pleural pressure swings, regional overdistension, pendelluft, and inflammation, with damage involving both lung and diaphragm. positive end-expiratory pressure (PEEP) and continuous positive airway pressure (CPAP) can homogenize ventilation, reduce strain-rate, and protect diaphragmatic mechanics, whereas uncontrolled effort worsens outcomes. Clinical investigations confirm that high drive and effort increase total lung stress despite protective tidal volumes and are linked to mortality, ventilator dependence, and complications such as pneumomediastinum. Emerging approaches include titrated pressure support and sedation and ventilatory assistance, neuromuscular blockade, phrenic nerve block, pharmacological drive modulation, prone positioning, and extracorporeal CO 2 removal. Strategies aimed at preserving diaphragm activity, such as electrical phrenic stimulation or inspiratory muscle training, further broaden protective options.SummaryP-SILI arises when excessive inspiratory effort translates into injurious lung and diaphragm stress. Preventive strategies should not abolish but shape effort, integrating ventilatory settings, sedation, and drive-modulating interventions across the continuum from the acute phase to weaning and rehabilitation.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41359372 · DOI · PMC12746771
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Diagnosis and management of bronchopulmonary dysplasia [5]
- Research article Pulmonary hypertension in bronchopulmonary dysplasia [6]
- Research article Static and Dynamic Contributors to Ventilator-induced Lung Injury in Clinical Practice. Pressure, Energy, and Power [7]
- Research article Oxygen radical disease in the newborn, revisited: Oxidative stress and disease in the newborn period [8]
- Research article Volume-targeted versus pressure-limited ventilation in neonates [9]
- Research article Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis [10]
References
- Khan IS, Molina C, Ren X, Auyeung VC, Cohen M, Tsukui T, et al.. Impaired myofibroblast proliferation is a central feature of pathologic post-natal alveolar simplification. . 2024. PMID 39660606 · DOI · PMC11634066
- Yu H, Li D, Zhao X, Fu J. Fetal origin of bronchopulmonary dysplasia: contribution of intrauterine inflammation. . 2024. PMID 39227783 · DOI · PMC11373297
- Ding KL, Smith C, Seedorf G, Abman SH. Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model. . 2025. PMID 39394424 · DOI · PMC12119323
- Balzani E, Alcala GC, Bellani G, Pesenti A. Patient self-inflicted lung injury an important phenomenon. . 2026. PMID 41359372 · DOI · PMC12746771
- Gilfillan M, Bhandari A, Bhandari V. Diagnosis and management of bronchopulmonary dysplasia. BMJ. 2021. PMID 34670756 · DOI
- Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M, et al.. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021. PMID 32521539 · DOI · PMC7979539
- Marini JJ, Rocco PRM, Gattinoni L. Static and Dynamic Contributors to Ventilator-induced Lung Injury in Clinical Practice. Pressure, Energy, and Power. Am J Respir Crit Care Med. 2020. PMID 31665612 · DOI · PMC7124710
- Perez M, Robbins ME, Revhaug C, Saugstad OD. Oxygen radical disease in the newborn, revisited: Oxidative stress and disease in the newborn period. Free Radic Biol Med. 2019. PMID 30954546 · DOI · PMC6791125
- Klingenberg C, Wheeler KI, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation in neonates. Cochrane Database Syst Rev. 2017. PMID 29039883 · DOI · PMC6485452
- Ramaswamy VV, Bandyopadhyay T, Nanda D, Bandiya P, Ahmed J, Garg A, et al.. Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2021. PMID 33720274 · DOI · PMC7961472
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-11-04.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.